Current Report Filing (8-k)
April 16 2018 - 7:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 16, 2018
GALECTIN THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Nevada
|
|
001-31791
|
|
04-3562325
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240
NORCROSS, GA 30071
(Address of principal executive office) (zip code)
Registrants telephone number, including area code: (678)
620-3186
N/A
(Former name or
former address, if changed since last report)
Check the
appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
SECTION 7 REGULATION FD
Item 7.01
|
Regulation FD Disclosure.
|
On April 16, 2018, Galectin Therapeutics Inc. (the
Company) posted to its website a presentation of results of its
NASH-CX
clinical trial attached hereto as Exhibit 99.1.
The information in this report is being furnished pursuant to this Item 7.01 and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or
under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report.
SECTION 8 OTHER ITEMS
On April 16, 2018, the Company issued the press release attached
hereto as Exhibit 99.2.
SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Galectin Therapeutics Inc.
|
|
|
|
|
Date: April 16, 2018
|
|
|
|
By:
|
|
/s/ Jack W. Callicutt
|
|
|
|
|
|
|
Jack W. Callicutt
|
|
|
|
|
|
|
Chief Financial Officer
|
- 3 -
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Sep 2023 to Sep 2024